EP. 11: Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center
April 4th 2025
Experts discuss the key characteristics of the patient, disease, and CAR T-cell construct considered when determining if a patient with minimal residual disease (MRD)–negative complete response (CR) post chimeric antigen receptor (CAR) T-cell therapy should proceed to consolidative stem cell transplant (SCT), the circumstances under which CAR T-cell therapy could be considered a standalone treatment, principal risk factors for relapsed disease and strategies for prevention or mitigation, the impact of early T-cell exhaustion on the decision to proceed with allogeneic hematopoietic SCT (allo-HSCT) in previous CAR T-cell recipients, and other factors that influence that decision.
